Volume | 1,224,931 |
|
|||||
News | - | ||||||
Day High | 3.38 | Low High |
|||||
Day Low | 3.22 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
AbCellera Biologics Inc | ABCL | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
3.32 | 3.22 | 3.38 | 3.23 | 3.33 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
7,446 | 1,224,931 | US$ 3.27 | US$ 4,000,488 | - | 3.22 - 8.05 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
18:52:27 | formt | 1,202 | US$ 3.20 | USD |
AbCellera Biologics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
934.62M | 289.36M | - | 38.03M | -146.4M | -0.51 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
AbCellera Biologics News
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ABCL Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 3.68 | 3.76 | 3.22 | 3.44 | 2,028,007 | -0.48 | -13.04% |
1 Month | 3.82 | 4.335 | 3.22 | 3.72 | 1,488,332 | -0.62 | -16.23% |
3 Months | 4.70 | 4.7499 | 3.22 | 3.94 | 1,318,342 | -1.50 | -31.91% |
6 Months | 5.17 | 6.055 | 3.22 | 4.67 | 1,417,828 | -1.97 | -38.10% |
1 Year | 7.50 | 8.05 | 3.22 | 5.40 | 1,762,295 | -4.30 | -57.33% |
3 Years | 26.6021 | 26.6021 | 3.22 | 9.93 | 1,995,263 | -23.40 | -87.97% |
5 Years | 61.00 | 71.91 | 3.22 | 12.19 | 1,873,521 | -57.80 | -94.75% |
AbCellera Biologics Description
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners. |